Orion Biotechnology

Executive Summary

Orion Biotechnology is a private Swiss biopharmaceutical company focused on developing first-in-class biologics targeting GPR75, a novel G protein-coupled receptor implicated in obesity. The company has two preclinical candidates that have demonstrated consistent efficacy in animal models, showing significant weight loss and metabolic improvements without the tolerability issues associated with current GLP-1-based therapies. Both assets are being advanced toward clinical development, with plans to initiate a Phase 1/2 trial in the coming months. Given the high unmet need in obesity and the potential for a differentiated mechanism, Orion's programs could represent a significant advancement if clinical data confirm preclinical findings. As a private entity, the company's progress is closely watched by investors seeking novel obesity targets.

Upcoming Catalysts (preview)

• Q4 2026Regulatory approval to initiate Phase 1/2 trial (CTA/IND submission)40% success
• Q1 2027First patient dosed in Phase 1/2 obesity trial50% success
• H2 2027Interim safety and efficacy data from Phase 1/2 trial30% success